Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Non-cash Items (2016 - 2025)

Historic Non-cash Items for Intellia Therapeutics (NTLA) over the last 10 years, with Q3 2025 value amounting to $4.1 million.

  • Intellia Therapeutics' Non-cash Items fell 12.19% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year decrease of 12.19%. This contributed to the annual value of $350000.0 for FY2024, which is 9128.75% down from last year.
  • According to the latest figures from Q3 2025, Intellia Therapeutics' Non-cash Items is $4.1 million, which was down 12.19% from $255000.0 recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Non-cash Items high stood at $974.5 million for Q2 2021, and its period low was $20000.0 during Q1 2025.
  • Its 5-year average for Non-cash Items is $129.5 million, with a median of $4.1 million in 2024.
  • In the last 5 years, Intellia Therapeutics' Non-cash Items soared by 1816045.91% in 2021 and then tumbled by 9992.76% in 2025.
  • Over the past 5 years, Intellia Therapeutics' Non-cash Items (Quarter) stood at $493.0 million in 2021, then crashed by 99.35% to $3.2 million in 2022, then soared by 1016.73% to $35.9 million in 2023, then crashed by 99.03% to $350000.0 in 2024, then skyrocketed by 1069.09% to $4.1 million in 2025.
  • Its Non-cash Items stands at $4.1 million for Q3 2025, versus $255000.0 for Q2 2025 and $20000.0 for Q1 2025.